shortagewatch

Home / Companies / Cooper Consumer

Company family

Cooper Consumer: medicine shortages

As of 2 Nov 2026, 11 Cooper Consumer products have a reported shortage across 7 countries, covering 6 medicines.

Products short11rank #171 of 464
Medicines6active ingredients
Countries7/16
New in 90 days60 vs market pace
Typical duration3 monthsmedian so far
Manufacturing78%demand-driven 11%

Where

Italy1Spain2Ireland1Austria1Belgium3Czechia2Norway1

Which therapeutic classes

Digestive tract and metabolism3Cardiovascular system3Sensory organs2Respiratory system2Dermatologicals1

Why, compared with all companies

Manufacturing problemIncreased demandActive ingredient shortageDistribution or logisticsCommercial decision or withdrawalRegulatory or licensingOtherNot stated
Cooper ConsumerCooper Consumer: Manufacturing problem 7 (64%)64%Cooper Consumer: Increased demand 1 (9%)9%Cooper Consumer: Regulatory or licensing 1 (9%)9%Cooper Consumer: Not stated 2 (18%)18%All companiesAll companies: Manufacturing problem 4,893 (36%)36%All companies: Increased demand 1,873 (14%)14%All companies: Active ingredient shortage 367 (3%)All companies: Distribution or logistics 336 (2%)All companies: Commercial decision or withdrawal 435 (3%)All companies: Regulatory or licensing 131 (1%)All companies: Other 1,244 (9%)9%All companies: Not stated 4,221 (31%)31%

Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.

When its current shortages began

01235Dec: 0Jan ’25: 0Feb: 0FebMar: 0Apr: 0May: 0MayJun: 0Jul: 0Aug: 0AugSep: 0Oct: 1Nov: 1NovDec: 0Jan ’26: 0Feb: 0FebMar: 0Apr: 0May: 0MayJun: 2Jul: 1Aug: 1AugSep: 2Oct: 3Nov: 0Nov

Against its peers

Viatris995Teva903Sandoz599Pfizer491Accord (Intas)484Stada349Zentiva340Fresenius Kabi339Apotex326Sun Pharma250Aurobindo226Towa (Pensa)201Krka187Sanofi158Cooper Consumer11

Breadth vs depth

1101001,00010,0001101001,000Products short (log scale)Medicines affected (log scale)Viatris: 995 / 248ViatrisTeva: 903 / 289TevaSandoz: 599 / 198SandozPfizer: 491 / 122PfizerAccord (Intas): 484 / 151Accord (Intas)Stada: 349 / 140Zentiva: 340 / 159ZentivaFresenius Kabi: 339 / 81Apotex: 326 / 152Sun Pharma: 250 / 77Aurobindo: 226 / 111Towa (Pensa): 201 / 102Krka: 187 / 67Sanofi: 158 / 45Jamp: 151 / 74Baxter: 149 / 27Sawai: 148 / 68Hikma: 126 / 44Glenmark: 105 / 39Sanis: 98 / 54Cheplapharm: 86 / 28GSK: 85 / 38Advanz (Amdipharm): 81 / 24Nichi-Iko: 77 / 29Takeda: 76 / 10Johnson & Johnson: 75 / 19Neuraxpharm: 75 / 19Novartis: 70 / 32Bayer: 68 / 17Biomed: 64 / 21Daiichi Sankyo: 59 / 18Orifarm: 59 / 40Medochemie: 56 / 14Pharmascience: 51 / 32Marcan: 51 / 16Doc Generici: 50 / 25B. Braun: 49 / 17AA Pharma: 46 / 26H E: 46 / 15Octapharma: 42 / 6Jv E: 42 / 1Kyowa Pharmaceutical: 42 / 16Novo Nordisk: 41 / 8Odan: 41 / 31Aspen: 41 / 13Sterop: 41 / 16Nipro: 41 / 17Dr. Reddy's: 40 / 24Organon: 40 / 20Laboratoire Riva: 40 / 23Kern Pharma: 40 / 30Bausch Health: 39 / 30Bracco: 38 / 6G.L.: 38 / 13Tatsumi Kagaku: 38 / 24Otsuka: 37 / 4Eli Lilly: 37 / 12Piramal Critical: 35 / 13Imuna Pharm: 35 / 4AbbVie: 34 / 15Medical Valley: 34 / 8Orion: 34 / 24Rowex: 34 / 19Takata Pharmaceutical: 33 / 17Aristo: 32 / 16Norgine: 32 / 3Gedeon Richter: 31 / 11Eql: 31 / 9Guerbet: 30 / 5Lukas Heil-Betriebsst: 30 / 0Roche: 29 / 14Omega: 29 / 18Bgp: 29 / 18Holsten -: 29 / 3Menarini: 29 / 17Paladin: 28 / 17Grifols: 28 / 9Ge: 28 / 6Merck & Co. (MSD): 27 / 14Ferring: 27 / 7Cooper Consumer: 11 / 6Cooper Consumer

Further right: more products short. Higher: more different medicines affected.

Medicines short

MedicineWhere this company is shortProductsEarliest startMain reasonShort anywhere
Azelastine230 Jun 2026Not stated3/16
Ispaghula (Psylla Seeds)210 Jun 2026Not stated2/16
Azelastine129 Sep 2026Manufacturing problem1/16
Cyclizine120 Oct 2025Regulatory or licensing1/16
Macrogol, Combinations117 Nov 2025Manufacturing problem7/16
Povidone-Iodine116 Oct 2026Increased demand4/16

Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.